21 October 2025

To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street – Fort
Mumbai 400 001

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th floor
Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Sub: Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30 of the Listing Regulations, we hereby inform you that Advagen Holdings Inc. ("Advagen"), a wholly owned subsidiary of Rubicon Research Limited ("Company"), has entered into a definitive agreement with GEn1E Lifesciences Inc. ("Gen1E"), to acquire Series Prime Preferred Stock in tranches, for a total consideration of up to USD 3 million.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 on the captioned subject are enclosed to this intimation as Annexure I.

We request you take the above information on records.

Thanking you,

Yours faithfully,

For Rubicon Research Limited

Nitin Jajodia
Digitally signed by Nitin Jajodia
Date: 2025.10.21 17:37:07 +05'30'

Nitin Jajodia
Chief Financial Officer
Place: Thane

Annexure I

Details under Regulation 30 of the Listing Regulations read along with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Name of target entity: Gen1e Lifesciences Inc. Turnover: Gen1e is a pre-revenue stage Company with zero revenue.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The transaction would be executed via Advagen Holdings Inc. ("Advagen"), a wholly owned subsidiary Company of Rubicon Research Limited ("Company") The Acquisition would not fall within related party transactions and the Company and / or its promoter / promoter group / group companies have no interest in Gen1E.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The transaction is a minority investment in Gen1E relating to the development of pharmaceutical products.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None

<table>
<tr><td>6.</td><td>Indicative time period for completion of the acquisition</td><td rowspan="2">Total consideration of up to USD 3 million as a combination of cash consideration of USD 2 million in 2 tranches to be completed by 31 March 2026; and up to USD 1 million against development activities undertaken by the Company/ Advagen up to 31 December 2027 under a milestone-based share issuance model.</td></tr>
<tr><td>7.</td><td>Consideration - whether cash consideration or share swap or any other form and details of the same;</td></tr>
<tr><td>8.</td><td>Cost of acquisition and/or the price at which the shares are acquired;</td><td>United States Dollars 3 million.</td></tr>
<tr><td>9.</td><td>Percentage of shareholding / control acquired and / or number of shares acquired;</td><td>Series Prime Preferred Stock, convertible into approximately 2.2% of Gen1E's common stock ownership subject to achievement of all milestones.</td></tr>
<tr><td>10.</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)</td><td>Brief Background:

Gen1E is a pharmaceutical company with a pipeline of product candidates under development. GEn1E is based in Palo Alto, California, with a laboratory in Mountain View, California, USA.

Date of Incorporation: May 23, 2018

Country of presence: United States of America

History of last 3 years' turnover: NIL (Gen1e is a pre-revenue stage company).</td></tr>
</table>